Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Dr Simon Hirst

Simon is Sygnature’s founder and Chief Executive Officer. He is a medicinal chemist with 30 years’ experience in the pharmaceutical industry and has been engaged in the full spectrum of drug discovery programmes – from hit to lead libraries, hit-to-lead campaigns, all the way to successful lead optimisation projects and candidate drug selection.

He has broad-ranging experience of research from AstraZeneca and OSI Pharmaceuticals; as well CombiPure Ltd., where he served as Managing Director and Director of Chemistry. Simon has a BSc (Hons.) in chemistry and a PhD in synthetic organic chemistry from the University of Nottingham, and undertook post-doctoral research at the University of Pittsburgh.

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…